M. Valeria Cáceres

Statistics

Publications

Citations

274

H-Index

Active since

2022

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Creighton University

University of California, Irvine

Université Laval

Institut Curie

M. Valeria Cáceres is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pembrolizumab therapy, and cervical recurrence.

ORCID

Publications per year

2022–2023

Publications

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari et al. · Journal of Clinical Oncology · 2023 · 236 citations

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo, Coraline Dubot, Domenica Lorusso et al. · Obstetrical & Gynecological Survey · 2022 · 21 citations

Medicine, Oncology, Pharmacotherapy +17

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari et al. · Journal of Clinical Oncology · 2023 · 17 citations

Medicine, Oncology, Pharmacology +15

1–3 of 3